Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUZERN: Niraparib plus aromatase inhibitors in HR-positive/HER2-negative metastatic breast cancer with BRCA mutation or HRD
2017-004323-72Phase 2Active
- Sponsor
- MEDSIR
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in breast cancer, sponsored by MEDSIR. Primary endpoint: Clinical benefit rate. Started Dec 2019; status: active.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004323-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004323-72.